Access to anticancer drugs: Many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme

Internal Medicine Journal

Volumn 42, Issue 11, 2012, Pages 1224-1229

  Mellor, J D ^a   Van Koeverden, P ^a   Yip, S W K ^a   Thakerar, A ^a   Kirsa, S W ^a   Michael, M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Chemotherapy; Haematology; Off label; Oncology; PBS; Unlicensed

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PROTOCOL; CONSENSUS; DIGESTIVE SYSTEM CANCER; DRUG DOSE REGIMEN; EVIDENCE BASED MEDICINE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEALTH CARE ACCESS; HUMAN; LUNG CANCER; OFF LABEL DRUG USE; PEER REVIEW; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SARCOMA; SKIN CANCER; TERTIARY HEALTH CARE;

ACADEMIC MEDICAL CENTERS; ANTINEOPLASTIC AGENTS; CANCER CARE FACILITIES; CLINICAL PROTOCOLS; DRUG APPROVAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; FINANCING, GOVERNMENT; GUIDELINE ADHERENCE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; NEOPLASMS; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; SOCIOECONOMIC FACTORS; TERTIARY CARE CENTERS; VICTORIA;

EID: 84869799975     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02751.x     Document Type: Article

References (8)

1. Mellor JD, Bensted KE, Chan PL. Off-label and unlicensed prescribing in a specialist oncology centre in Australia. Asia Pac J Clin Oncol 2009; 5: 242-246.
2. Mullins CD, Montgomery R, Tunis S. Uncertainty in assessing value of oncology treatments. Oncologist 2010; 15(Suppl 1): 58-64.
3. Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O etal. Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey. Tumori 2009; 95: 647-651.
4. Leveque D. Off-label use of anticancer drugs. Lancet Oncol 2008; 9: 1102-1107.
5. Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics 2009; 37: 476-486, 396.
6. Minghetti P, Palmieri I, Selmin F. When authorized medicinal products are not available: possible alternatives to meet legitimate expectations of patients. JPHSR 2010; 1: 107-112.
7. Abernethy AP, Raman G, Balk EM, Hammond JM, Orlando LA, Wheeler JL etal. Systematic review: reliability of compendia methods for off-label oncology indications. Ann Intern Med 2009; 150: 336-343.
8. Stephen R, Knopf K, Reynolds M, Luo W, Fraeman K. Off-label use of oncology drugs in a community oncology EMR database. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th International Meeting; Orlando, FL; 2009.